CO5270007A1 - Composiciones que tienen suministro mejorado de activos - Google Patents
Composiciones que tienen suministro mejorado de activosInfo
- Publication number
- CO5270007A1 CO5270007A1 CO00001049A CO00001049A CO5270007A1 CO 5270007 A1 CO5270007 A1 CO 5270007A1 CO 00001049 A CO00001049 A CO 00001049A CO 00001049 A CO00001049 A CO 00001049A CO 5270007 A1 CO5270007 A1 CO 5270007A1
- Authority
- CO
- Colombia
- Prior art keywords
- compositions
- improved
- solvent
- active compound
- pharmaceutically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/12—Mucolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Abstract
La presente invención se refiere a una composición desde 0.075 hasta 25% de un compuesto farmacéuticamente activo mono-molecular no ionizado en un disolvente anhídrido, hidrófilo, miscible en agua en donde el compuesto farmacéuticamente activo en su estado no ionizado tiene un porcentaje de valor de solubilidad en el disolvente a temperatura ambiente que es igual o superior a 0.075% y en donde el disolvente es seleccionado de propilenglicol, etanol, polietilenglicol, carbonato de propileno, monoetiléter de dietilenglicol, poloxamer, glicofurol, glicerol y mezclas de éstos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11537899P | 1999-01-11 | 1999-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5270007A1 true CO5270007A1 (es) | 2003-04-30 |
Family
ID=22361013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO00001049A CO5270007A1 (es) | 1999-01-11 | 2000-01-11 | Composiciones que tienen suministro mejorado de activos |
Country Status (15)
Country | Link |
---|---|
US (1) | US6846495B2 (es) |
EP (1) | EP1140093A2 (es) |
JP (1) | JP2002534463A (es) |
KR (1) | KR100511730B1 (es) |
CN (1) | CN1203854C (es) |
AU (1) | AU762366B2 (es) |
BR (1) | BR0007445A (es) |
CA (1) | CA2356881C (es) |
CO (1) | CO5270007A1 (es) |
CZ (1) | CZ20012491A3 (es) |
HU (1) | HUP0105021A3 (es) |
NO (1) | NO20013442L (es) |
PE (1) | PE20001415A1 (es) |
TR (1) | TR200101927T2 (es) |
WO (1) | WO2000041693A2 (es) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001066089A2 (en) * | 2000-03-09 | 2001-09-13 | Gw Pharma Limited | Pharmaceutical compositions comprising cannabis |
EP1321140B1 (en) * | 2000-08-25 | 2005-04-06 | Kowa Company, Ltd. | Ibuprofen solutions for capsule-filling and capsule preparations |
US7138133B2 (en) | 2001-10-10 | 2006-11-21 | The Procter & Gamble Company | Orally administered liquid compositions |
US20070020330A1 (en) | 2004-11-24 | 2007-01-25 | Medpointe Healthcare Inc. | Compositions comprising azelastine and methods of use thereof |
PT2486942T (pt) | 2004-11-24 | 2019-01-18 | Meda Pharmaceuticals Inc | Composições que compreendem azelastina e seus métodos de utilização |
NZ554779A (en) * | 2005-02-01 | 2011-02-25 | Troikaa Pharmaceuticals Ltd | Injectable preparations of diclofenac ((2,6-dichloranilino)phenylacetic acid) and its pharmaceutically acceptable salts |
JP5529529B2 (ja) | 2006-04-05 | 2014-06-25 | インターコンチネンタル グレート ブランズ エルエルシー | 口腔輸送システムに用いるリン酸カルシウム錯体及び塩 |
JP2009532478A (ja) * | 2006-04-05 | 2009-09-10 | キャドバリー アダムス ユーエスエー エルエルシー | 酸含有菓子組成物中のリン酸カルシウム錯体 |
PL2076142T3 (pl) * | 2006-06-29 | 2020-05-18 | Intercontinental Great Brands Llc | Usprawniona przecinarka łańcuchowa do ciągłego formowania kawałków gumy do żucia z nadzieniem |
US20090029018A1 (en) * | 2007-07-27 | 2009-01-29 | Cadbury Adams Usa Llc | Method and apparatus for processing confectionery products |
DE102007000521A1 (de) * | 2007-10-18 | 2009-04-23 | Renate Conrad | Hustenpräparat |
ES2393224T5 (es) † | 2008-02-08 | 2020-09-14 | Procter & Gamble | Proceso para fabricar una bolsa soluble en agua |
WO2014037832A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment of epilepsy and neurological diseases |
WO2013168021A1 (en) | 2012-05-07 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders |
US9399634B2 (en) | 2012-05-07 | 2016-07-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of depression |
CA2872975A1 (en) | 2012-05-07 | 2013-11-14 | Cellixbio Private Limited | Compositions and methods for the treatment of neurological disorders |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013168025A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of blood clotting disorders |
WO2013167992A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of inflammatory disorders |
WO2013168023A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of parkinson's disease |
WO2013167991A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic disorders |
US9394288B2 (en) | 2012-05-10 | 2016-07-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of asthma and allergy |
US9573927B2 (en) | 2012-05-10 | 2017-02-21 | Cellix Bio Private Limited | Compositions and methods for the treatment of severe pain |
US9403857B2 (en) | 2012-05-10 | 2016-08-02 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
WO2013168001A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9339484B2 (en) | 2012-05-10 | 2016-05-17 | Cellix Bio Private Limited | Compositions and methods for the treatment of restless leg syndrome and fibromyalgia |
WO2013168002A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological conditions |
WO2013168012A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
WO2013167999A2 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurologic diseases |
US9346742B2 (en) | 2012-05-10 | 2016-05-24 | Cellix Bio Private Limited | Compositions and methods for the treatment of fibromyalgia pain |
WO2013168033A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treatment of neurologic diseases |
WO2013168011A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of chronic pain |
WO2013168014A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of familial amyloid polyneuropathy |
US9315478B2 (en) | 2012-05-10 | 2016-04-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
CA2873096A1 (en) | 2012-05-23 | 2013-11-28 | Cellixbio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2013175376A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of local pain |
CN104583182A (zh) | 2012-05-23 | 2015-04-29 | 塞利克斯比奥私人有限公司 | 用于治疗粘膜炎的组合物和方法 |
JP2015518854A (ja) | 2012-05-23 | 2015-07-06 | セリックスビオ プライヴェート リミテッド | 多発性硬化症の治療のための組成物および方法 |
WO2013175347A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of respiratory disorders |
US9434729B2 (en) | 2012-05-23 | 2016-09-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of periodontitis and rheumatoid arthritis |
US9108942B1 (en) | 2014-11-05 | 2015-08-18 | Mahesh Kandula | Compositions and methods for the treatment of moderate to severe pain |
US9187427B2 (en) | 2012-08-03 | 2015-11-17 | Cellix Bio Private Limited | N-substituted nicotinamide compounds and compositions for the treatment migraine and neurologic diseases |
WO2014037833A2 (en) | 2012-09-06 | 2014-03-13 | Mahesh Kandula | Compositions and methods for the treatment inflammation and lipid disorders |
GB201215988D0 (en) * | 2012-09-07 | 2012-10-24 | Reckitt Benckiser Healthcare Int Ltd | Pharmaceutical compositions comprising flurbiprofen |
SG11201407325YA (en) | 2012-09-08 | 2014-12-30 | Cellix Bio Private Ltd | Compositions and methods for treatment of inflammation and lipid disorders |
US9333187B1 (en) | 2013-05-15 | 2016-05-10 | Cellix Bio Private Limited | Compositions and methods for the treatment of inflammatory bowel disease |
WO2014195961A1 (en) | 2013-06-04 | 2014-12-11 | Mahesh Kandula | Compositions and methods for the treatment of diabetes and pre-diabetes |
US9096537B1 (en) | 2014-12-31 | 2015-08-04 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
SG11201706952VA (en) | 2014-09-26 | 2017-10-30 | Cellix Bio Private Ltd | Compositions and methods for the treatment of epilepsy and neurological disorders |
EP3201168B1 (en) | 2014-09-29 | 2020-03-18 | Cellix Bio Private Limited | Compounds and compositions for the treatment of multiple sclerosis |
EP3212626B1 (en) | 2014-10-27 | 2018-11-07 | Cellix Bio Private Limited | Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis |
US9284287B1 (en) | 2014-11-05 | 2016-03-15 | Cellix Bio Private Limited | Compositions and methods for the suppression of carbonic anhydrase activity |
US9321716B1 (en) | 2014-11-05 | 2016-04-26 | Cellix Bio Private Limited | Compositions and methods for the treatment of metabolic syndrome |
US9173877B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of local pain |
US9175008B1 (en) | 2014-11-05 | 2015-11-03 | Cellix Bio Private Limited | Prodrugs of anti-platelet agents |
US9150557B1 (en) | 2014-11-05 | 2015-10-06 | Cellix Bio Private Limited | Compositions and methods for the treatment of hyperglycemia |
US9290486B1 (en) | 2014-11-05 | 2016-03-22 | Cellix Bio Private Limited | Compositions and methods for the treatment of epilepsy |
US10208014B2 (en) | 2014-11-05 | 2019-02-19 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological disorders |
US9932294B2 (en) | 2014-12-01 | 2018-04-03 | Cellix Bio Private Limited | Compositions and methods for the treatment of multiple sclerosis |
EP3229820A4 (en) * | 2014-12-12 | 2018-07-11 | Ari Healthcare Pvt. Ltd. | A mouth freshener |
US9206111B1 (en) | 2014-12-17 | 2015-12-08 | Cellix Bio Private Limited | Compositions and methods for the treatment of neurological diseases |
CN110845355A (zh) | 2015-01-06 | 2020-02-28 | 塞尔利克斯生物私人有限公司 | 用于治疗炎症和疼痛的组合物和方法 |
US11234897B2 (en) * | 2017-03-27 | 2022-02-01 | DXM Pharmaceutical, Inc. | Packaged multi-dose liquid dextromethorphan hydrobromide formulation |
US11911517B2 (en) | 2018-05-16 | 2024-02-27 | Bayer Healthcare Llc | High concentration suspension formulation for cold and flu soft gel capsule medications |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL272604A (es) * | 1960-12-28 | |||
US4136163A (en) | 1971-02-04 | 1979-01-23 | Wilkinson Sword Limited | P-menthane carboxamides having a physiological cooling effect |
CA1027347A (en) | 1972-07-20 | 1978-03-07 | David G. Rowsell | Compounds having a physiological cooling effect and compositions containing them |
SE7812207L (sv) | 1977-12-01 | 1979-06-02 | Welsh Nat School Med | Apparat, forfarande och framstellda produkter for anvendning vid administration av antihistaminer |
US4474985A (en) | 1981-07-06 | 1984-10-02 | Monsanto Company | Purification of N-acetyl aminophenols |
JPS5888334A (ja) | 1981-11-20 | 1983-05-26 | Takasago Corp | 3−l−メントキシプロパン−1、2−ジオ−ル |
US4478822A (en) | 1983-05-16 | 1984-10-23 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474752A (en) | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
GB8629567D0 (en) | 1986-12-10 | 1987-01-21 | Boots Co Plc | Therapeutic agents |
IE59934B1 (en) | 1987-06-19 | 1994-05-04 | Elan Corp Plc | Liquid suspension for oral administration |
US4883660A (en) * | 1988-10-17 | 1989-11-28 | Thames Pharmacal Co., Inc. | Gel bases for pharmaceutical compositions |
US5196486A (en) | 1989-03-17 | 1993-03-23 | Nalco Chemical Company | Alkoxylated vinyl polymer demulsifiers |
US5100898A (en) | 1990-01-25 | 1992-03-31 | Richardson-Vicks Inc. | Antitussive liquid compositions containing dyclonine |
AU663857B2 (en) * | 1990-10-31 | 1995-10-26 | Procter & Gamble Company, The | Dextromethorphan antitussive compositions |
US5196436A (en) | 1990-10-31 | 1993-03-23 | The Procter & Gamble Company | Dextromethorphan antitussive compositions |
US5141961A (en) | 1991-06-27 | 1992-08-25 | Richrdson-Vicks Inc. | Process for solubilizing difficulty soluble pharmaceutical actives |
AU6086794A (en) | 1993-02-18 | 1994-09-14 | Warner-Lambert Company | Cold/sinus preparation consisting of phenindamine tartarate with or without therapeutic agents |
US5505961A (en) | 1993-08-05 | 1996-04-09 | R. P. Scherer Corporation | Gelatin capsules containing a highly concentrated acetaminophen solution |
WO1995019759A1 (en) | 1994-01-24 | 1995-07-27 | The Procter & Gamble Company | Process for solubilizing difficultly soluble pharmaceutical actives |
US5510389A (en) | 1994-03-02 | 1996-04-23 | The Procter & Gamble Company | Concentrated acetaminophen solution compositions |
US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
US5616621A (en) | 1995-01-30 | 1997-04-01 | American Home Products Corporation | Taste masking liquids |
US5846557A (en) * | 1996-03-20 | 1998-12-08 | Cumberland Packing Corporation | Chewing gum containing cough suppressing agent |
US5955098A (en) | 1996-04-12 | 1999-09-21 | Flemington Pharmaceutical Corp. | Buccal non polar spray or capsule |
ES2234010T3 (es) * | 1996-04-12 | 2005-06-16 | Novadel Pharma Inc. | Aerosol bucal polar. |
SE9601528D0 (sv) * | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as antitissue agent |
US6027746A (en) * | 1997-04-23 | 2000-02-22 | Warner-Lambert Company | Chewable soft gelatin-encapsulated pharmaceutical adsorbates |
AU7916798A (en) | 1997-05-22 | 1998-12-11 | Boots Company Plc, The | Pharmaceutical compositions of flurbiprofen and burn-masking agent for treating sore throat |
DE69738333T2 (de) | 1997-10-01 | 2008-11-27 | Novadel Pharma Inc. | Nichtpolares Spray zur bukkalen Verabreichung |
-
1999
- 1999-12-20 US US09/466,950 patent/US6846495B2/en not_active Expired - Fee Related
-
2000
- 2000-01-10 HU HU0105021A patent/HUP0105021A3/hu unknown
- 2000-01-10 KR KR10-2001-7008796A patent/KR100511730B1/ko not_active IP Right Cessation
- 2000-01-10 EP EP00908243A patent/EP1140093A2/en not_active Withdrawn
- 2000-01-10 AU AU29627/00A patent/AU762366B2/en not_active Ceased
- 2000-01-10 PE PE2000000017A patent/PE20001415A1/es not_active Application Discontinuation
- 2000-01-10 WO PCT/US2000/000575 patent/WO2000041693A2/en not_active Application Discontinuation
- 2000-01-10 JP JP2000593304A patent/JP2002534463A/ja active Pending
- 2000-01-10 TR TR2001/01927T patent/TR200101927T2/xx unknown
- 2000-01-10 CZ CZ20012491A patent/CZ20012491A3/cs unknown
- 2000-01-10 CA CA2356881A patent/CA2356881C/en not_active Expired - Fee Related
- 2000-01-10 CN CNB008026920A patent/CN1203854C/zh not_active Expired - Fee Related
- 2000-01-10 BR BR0007445-4A patent/BR0007445A/pt not_active Application Discontinuation
- 2000-01-11 CO CO00001049A patent/CO5270007A1/es not_active Application Discontinuation
-
2001
- 2001-07-11 NO NO20013442A patent/NO20013442L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
HUP0105021A3 (en) | 2003-02-28 |
KR20010093255A (ko) | 2001-10-27 |
CA2356881C (en) | 2012-02-28 |
AU762366B2 (en) | 2003-06-26 |
US6846495B2 (en) | 2005-01-25 |
CZ20012491A3 (cs) | 2001-12-12 |
HUP0105021A2 (hu) | 2002-05-29 |
US20030139437A1 (en) | 2003-07-24 |
JP2002534463A (ja) | 2002-10-15 |
CA2356881A1 (en) | 2000-07-20 |
BR0007445A (pt) | 2001-10-16 |
AU2962700A (en) | 2000-08-01 |
TR200101927T2 (tr) | 2001-11-21 |
WO2000041693A2 (en) | 2000-07-20 |
EP1140093A2 (en) | 2001-10-10 |
PE20001415A1 (es) | 2001-01-05 |
NO20013442L (no) | 2001-09-11 |
CN1203854C (zh) | 2005-06-01 |
CN1336823A (zh) | 2002-02-20 |
NO20013442D0 (no) | 2001-07-11 |
KR100511730B1 (ko) | 2005-08-31 |
WO2000041693A3 (en) | 2000-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5270007A1 (es) | Composiciones que tienen suministro mejorado de activos | |
PE20010627A1 (es) | Composiciones que tienen estabilidad mejorada | |
BR9909796A (pt) | Composição farmacêutica | |
DE60131088D1 (de) | Gelierende wässrige pharmazeutische zusammensetzungen | |
BG106439A (en) | Pharmaceutical composition of improved solubility and oral absorptivity, containing benzamide derivative | |
BRPI0400721A (pt) | Composições que contêm sucralose | |
ATE297221T1 (de) | Topisch applizierbare zusammensetzungen mit externer wirkstoffdepotbildung, deren herstellung sowie deren verwendung | |
BRPI0406905A (pt) | Espuma de fosfato de clindamicina | |
CY1114631T1 (el) | Φαρμακοτεχνικες μορφες εχινοκανδινης που περιεχουν επιφανειοδραστικα που σχηματιζουν μικκυλιο | |
EP1340755A4 (en) | AGENT WITH EFFECT AGAINST HELICOBACTER | |
MX2008001496A (es) | Composiciones de atomizacion. | |
WO2002101848A3 (de) | Kühlmittel für kühlsysteme in brennstoffzellenantrieben enthaltend azolderivate | |
ATE275393T1 (de) | Feste dispersionen mit nitrataktiven wirkstoffen | |
CO5430216A1 (es) | Composiciones que tienen estabilidad mejorada de activos farmaceuticos | |
RS50046B (sr) | Farmaceutske kompozicije tizoksanida i nitazoksanida | |
BRPI0418115A (pt) | formulação lìquida estável de hormÈnio de crescimento | |
UY27979A1 (es) | Indoles sustituidos en posición 2,4 | |
EP1250925A3 (en) | Nasal spray containing ondansetron hydrochloride | |
CL2004001325A1 (es) | Una composicion farmaceutica de aerosol que comprende cilesonida solubilizada en un propelente hidrofluorocarbono y un co-solvente, de preferencia etanol, util como antiinflamatorio de las vias aereas. | |
PE20040471A1 (es) | Formulaciones de liberacion prolongada en forma de suspension | |
EP1284272A4 (en) | Estra-1,3,5 (10) -triene | |
PE20001424A1 (es) | Composiciones que tienen estabilidad mejorada | |
ATE430571T1 (de) | Wässrige pharmazeutische formulierungen von wasserlöslichen prodrugs von propofol- verbindungen | |
NZ514073A (en) | Taxane formulations having improved solubility | |
PT1171100E (pt) | Composicao farmaceutica solubilizada para administracao parenteral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |